PH26613A - A method for the treatment of bacterial and fungal infections using tumor necrosis factor-alpha infective agents - Google Patents

A method for the treatment of bacterial and fungal infections using tumor necrosis factor-alpha infective agents Download PDF

Info

Publication number: PH26613A
Authority: PH; Philippines
Prior art keywords: alpha; tumor necrosis; necrosis factor; patient; treatment
Prior art date: 1986-06-16

Application number

PH35409A

Other languages

English (en)

Inventor

Michael Angen Palladino

Arthur J Amman

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-16

Filing date

1987-06-15

Publication date

1992-08-19

1987-06-15 Application filed by Genentech Inc filed Critical Genentech Inc

1992-08-19 Publication of PH26613A publication Critical patent/PH26613A/en

Links

108060008682 Tumor Necrosis Factor Proteins 0.000 title claims description 80
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title claims description 80
238000000034 method Methods 0.000 title claims description 19
230000001580 bacterial effect Effects 0.000 title claims description 7
208000035143 Bacterial infection Diseases 0.000 title claims description 4
206010017533 Fungal infection Diseases 0.000 title claims description 4
208000031888 Mycoses Diseases 0.000 title claims description 4
208000022362 bacterial infectious disease Diseases 0.000 title claims description 4
230000001524 infective effect Effects 0.000 title description 2
210000003622 mature neutrocyte Anatomy 0.000 claims description 54
208000016532 chronic granulomatous disease Diseases 0.000 claims description 41
102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 38
210000001539 phagocyte Anatomy 0.000 claims description 21
208000015181 infectious disease Diseases 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
230000000242 pagocytic effect Effects 0.000 claims description 6
241000222122 Candida albicans Species 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims description 3
239000003242 anti bacterial agent Substances 0.000 claims description 3
229940095731 candida albicans Drugs 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 3
241001225321 Aspergillus fumigatus Species 0.000 claims description 2
206010007882 Cellulitis Diseases 0.000 claims description 2
241000588724 Escherichia coli Species 0.000 claims description 2
206010024652 Liver abscess Diseases 0.000 claims description 2
206010035664 Pneumonia Diseases 0.000 claims description 2
241000191967 Staphylococcus aureus Species 0.000 claims description 2
230000004913 activation Effects 0.000 claims description 2
229940091771 aspergillus fumigatus Drugs 0.000 claims description 2
201000003265 lymphadenitis Diseases 0.000 claims description 2
241000588915 Klebsiella aerogenes Species 0.000 claims 1
241000607715 Serratia marcescens Species 0.000 claims 1
230000003115 biocidal effect Effects 0.000 claims 1
229940092559 enterobacter aerogenes Drugs 0.000 claims 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 16
230000000638 stimulation Effects 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
230000000694 effects Effects 0.000 description 14
238000004519 manufacturing process Methods 0.000 description 13
239000000203 mixture Substances 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
239000011324 bead Substances 0.000 description 10
230000000699 topical effect Effects 0.000 description 10
238000009472 formulation Methods 0.000 description 8
102000004083 Lymphotoxin-alpha Human genes 0.000 description 7
108090000542 Lymphotoxin-alpha Proteins 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
230000002950 deficient Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
239000000969 carrier Substances 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
244000052769 pathogen Species 0.000 description 6
230000019254 respiratory burst Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
206010054094 Tumour necrosis Diseases 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
239000006071 cream Substances 0.000 description 5
230000003013 cytotoxicity Effects 0.000 description 5
231100000135 cytotoxicity Toxicity 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
206010028851 Necrosis Diseases 0.000 description 4
108010081690 Pertussis Toxin Proteins 0.000 description 4
206010057249 Phagocytosis Diseases 0.000 description 4
239000004599 antimicrobial Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
244000053095 fungal pathogen Species 0.000 description 4
239000004816 latex Substances 0.000 description 4
229920000126 latex Polymers 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
244000005700 microbiome Species 0.000 description 4
230000017074 necrotic cell death Effects 0.000 description 4
230000008782 phagocytosis Effects 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
230000006433 tumor necrosis factor production Effects 0.000 description 4
FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
229920000392 Zymosan Polymers 0.000 description 3
229960005475 antiinfective agent Drugs 0.000 description 3
244000052616 bacterial pathogen Species 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000007758 minimum essential medium Substances 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000012049 topical pharmaceutical composition Substances 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
108010007568 Protamines Proteins 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
238000001994 activation Methods 0.000 description 2
238000007792 addition Methods 0.000 description 2
230000004075 alteration Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
102000043557 human IFNG Human genes 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000036284 oxygen consumption Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
230000015323 positive regulation of phagocytosis Effects 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
241000894007 species Species 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
241000239218 Limulus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
108010072542 endotoxin binding proteins Proteins 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
-1 oxygen radicals Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
231100000435 percutaneous penetration Toxicity 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
108010086652 phytohemagglutinin-P Proteins 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000007962 solid dispersion Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PH35409A 1986-06-16 1987-06-15 A method for the treatment of bacterial and fungal infections using tumor necrosis factor-alpha infective agents PH26613A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87473686A	1986-06-16	1986-06-16
US5393887A	1987-05-22	1987-05-22

Publications (1)

Publication Number	Publication Date
PH26613A true PH26613A (en)	1992-08-19

Family

ID=26732412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH35409A PH26613A (en)	1986-06-16	1987-06-15	A method for the treatment of bacterial and fungal infections using tumor necrosis factor-alpha infective agents

Country Status (8)

Country	Link
EP (1)	EP0250192A3 (de)
JP (1)	JPH07100662B2 (de)
AU (1)	AU598817B2 (de)
DK (1)	DK302887A (de)
IL (1)	IL82862A0 (de)
NZ (1)	NZ220686A (de)
PH (1)	PH26613A (de)
PT (1)	PT85076B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ219027A (en) *	1986-01-24	1989-09-27	Genentech Inc	Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
DE3613166A1 (de) *	1986-04-18	1987-10-29	Basf Ag	Verwendung von tnf zur herstellung von arzneimitteln
US5322699A (en) *	1991-02-04	1994-06-21	The Rockefeller University	Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3472793D1 (en) *	1983-12-26	1988-08-25	Asahi Chemical Ind	A novel physiologically active polypeptide
DE3423234A1 (de) *	1984-06-23	1986-02-06	Boehringer Ingelheim International GmbH, 6507 Ingelheim	Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (de) *	1984-07-05	1985-11-26	Genentech Inc
US4879111A (en) *	1986-04-17	1989-11-07	Cetus Corporation	Treatment of infections with lymphokines

1987
- 1987-06-12 PT PT85076A patent/PT85076B/pt unknown
- 1987-06-14 IL IL82862A patent/IL82862A0/xx unknown
- 1987-06-15 PH PH35409A patent/PH26613A/en unknown
- 1987-06-15 EP EP87305286A patent/EP0250192A3/de not_active Withdrawn
- 1987-06-15 AU AU74223/87A patent/AU598817B2/en not_active Expired
- 1987-06-15 DK DK302887A patent/DK302887A/da not_active Application Discontinuation
- 1987-06-15 NZ NZ220686A patent/NZ220686A/xx unknown
- 1987-06-16 JP JP62150069A patent/JPH07100662B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU7422387A (en)	1987-12-17
EP0250192A2 (de)	1987-12-23
NZ220686A (en)	1990-02-26
DK302887A (da)	1987-12-17
DK302887D0 (da)	1987-06-15
EP0250192A3 (de)	1988-02-10
JPH07100662B2 (ja)	1995-11-01
PT85076A (en)	1987-07-01
PT85076B (pt)	1990-07-31
AU598817B2 (en)	1990-07-05
JPS6354327A (ja)	1988-03-08
IL82862A0 (en)	1987-12-20

Publication	Publication Date	Title
Murray et al.	1987	In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes.
Dale et al.	1998	Effects of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) on neutrophil kinetics and function in normal human volunteers
Thueson et al.	1979	Histamine-releasing activity (HRA) I. Production by mitogen-or antigen-stimulated human mononuclear cells
Snyderman et al.	1977	Biologic and Biochemical Activities of Continuous Macrophage Cell Lines P388D1 and J774.
Schulkind et al.	1972	Transfer factor in the treatment of a case of chronic mucocutaneous candidiasis
Pabst et al.	1982	Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response.
Steinbeck et al.	1986	Activation of bovine neutrophils by recombinant interferon-γ
David et al.	1976	Macrophage activation by lymphocyte mediators and studies on the interaction of macrophage inhibitory factor (MIF) with its target cell
Ohno et al.	1970	The inhibition of lymphocyte blastogenesis by L-asparaginase
Kaplan et al.	1986	Effect of recombinant interferon-gamma on hydrogen peroxide-releasing capacity of monocyte-derived macrophages from patients with lepromatous leprosy.
KR20020016844A (ko)	2002-03-06	반응성 산소 대사산물 저해제를 이용한 세포독성 림프구의활성화 및 보호
Galgiani et al.	1984	Human polymorphonuclear-leukocyte inhibition of incorporation of chitin precursors into mycelia of Coccidioides immitis
Lukacs et al.	1985	Activation of neutrophils by antigen-induced lymphokine, with emphasis on antibody-independent cytotoxicity
KR20160113302A (ko)	2016-09-28	호중구감소증을 치료하기 위한 조성물 및 방법
AU598817B2 (en)	1990-07-05	Tumor necrosis factor alpha as treatment for infectious diseases
US20060127387A1 (en)	2006-06-15	Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
JPH06500558A (ja)	1994-01-20	組み換えコロニー刺激因子―１の使用
Waymack et al.	1988	Effect of prostaglandin E on immune function in multiple animal models
CA1316818C (en)	1993-04-27	Therapeutic compositions containing tumor necrosis factor-alpha
Lehrer et al.	2001	Biochemistry and function of monocytes and macrophages
Lawton et al.	1976	The effect of transfer factor on neutrophil function in chronic mucocutaneous candidiasis
Sullivan et al.	1992	Lipid complexing decreases amphotericin B inflammatory activation of human neutrophils compared with that of a desoxycholate-suspended preparation of amphotericin B (Fungizone)
EP1038529A2 (de)	2000-09-27	Wirkstoff zur Erhöhung der Chemokinproduktion
US20030198617A1 (en)	2003-10-23	Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
CA2538422A1 (en)	2005-03-24	Method to enhance hematopoiesis